Moreover, apigenin sensitizes primary patient-derived lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL) anti-tumor therapies, without affecting non-tumor cells [9]. This evidence concerns the gene TNFSF10 and neoplasm.